Pru

What Pru does

Pharmaceutical Research Unit (PRU), legally Arab Pharmaceutical Industry Consulting Co. (APIC), is a privately held contract research organization (CRO) headquartered in Amman, Jordan, founded in 1993. The company provides a full suite of clinical development services — bioequivalence/bioavailability (BE/BA) and pharmacokinetics studies, Phase I-IV clinical trials, bioanalytical services, regulatory and drug development consulting, medical writing, data management, statistical analysis, central laboratory services, IMP storage/distribution, and GCP/GLP/GDSP training — primarily to pharmaceutical and biotechnology sponsors developing both generic and innovative drugs across Asia, Africa, the EU, and the USA.

PRU operates two licensed clinical sites in Amman with more than 100 beds, an accredited diagnostic lab, temperature-controlled pharmacy, and emergency rooms, supported by LC-MS/MS, LC-MS, and UPLC instrumentation managed through Watson LIMS, an automated barcode sample-tracking system, and a participant recruitment platform integrated with the Jordan Food and Drug Administration (JFDA) database. Its validated bioanalytical method library of more than 250 methods and a healthy-volunteer database exceeding 5,000 participants underpin a stated throughput of 80+ BE/BA/PK studies per year and over 1,000 studies completed to date across 100,000+ processed samples.

The business model is B2B professional services on a quote-based pricing structure, sold via direct enterprise engagement to pharmaceutical and biotech sponsors. Revenue is generated per study and per service line, with geographic access to regulated markets enabled by a stack of accreditations that includes USFDA inspection with no observations (2020 and 2025), two EMA inspections (Belgian 2011, Spanish 2019), ANVISA certification (August 2025), Turkish MOH accreditation (since 2009, fourth inspection 2019), Malaysia NPRA listing (July 2020), GCC approval, and periodic JFDA inspections. Marketing is conducted primarily through industry events (e.g., GCC Regulatory Affairs Pharma Virtual Summit), a corporate website, LinkedIn, and YouTube. The company has no disclosed parent, no external funding rounds, and no M&A activity in the source data.

Name

Pru

Legal name

Arab Pharmaceutical Industry Consulting Co.

Website

https://pru.com.jo

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

Pharmaceutical Research Unit (PRU/APIC) is an Amman, Jordan-based contract research organization, founded 1993, that runs bioequivalence, bioavailability, Phase I-IV clinical trials, and bioanalytical services for pharmaceutical and biotech sponsors across Asia, Africa, the EU, and the USA under USFDA, EMA, ANVISA, and GCC accreditations.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Pharmaceutical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Investigator & Site Training / GCP Support (HLAGACAF)

Keywords

• Clinical research services
• Bioequivalence studies
• Pharmaceutical contract research
• Bioanalytical services
• Clinical trial management

Headquarters

HQ city

Amman

HQ country

Jordan

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Clinical Development Services: Comprehensive CRO services including bioequivalence/bioavailability studies, clinical trials management (Phase I-IV), bioanalysis, data management, PK/statistics, medical writing, and regulatory consulting for pharmaceutical companies
2. Bioequivalence Studies: Licensed clinical units with 102 beds across two sites, conducting bioequivalence, bioavailability and pharmacokinetics studies for generic and innovative drug development
3. Training Services: GCP, GLP, GDSP training and professional development programs for clinical research professionals
4. Cross Sectional Services: Medical writing, IRB/EC services, central laboratory services, IMP storage/distribution, data management, pharmacokinetics evaluation, and CTD/eCTD study reporting

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

PRU/APIC is a Contract Research Organization that conducts bioequivalence, bioavailability, and pharmacokinetics studies (BE/BA/PK) and Phase I-IV clinical trials for pharmaceutical and biotech sponsors. Its offerings span bioanalytical method development and validation using LC-MS/MS, LC-MS, and UPLC platforms, plus supporting services such as medical writing, data management, pharmacokinetics/statistics, IMP storage and distribution, IRB/EC services, and GCP/GLP/GDSP training. Clinical operations are delivered across two licensed clinical sites with 100+ beds in Amman, Jordan, serving sponsors in Asia, Africa, the EU, and the USA.

Product overview

PRU/APIC offers a comprehensive suite of biopharmaceutical services for drug development, structured as an integrated platform combining core clinical research offerings with supporting services. The core products include Bioequivalence Studies (BE/BA), Clinical Trials (Phase I-IV), and Bioanalytical Services, which form the primary revenue-generating service lines. These are supported by Training Services and Cross Sectional Services (covering medical writing, IRB/EC services, data management, PK/statistics, and regulatory reporting). The company operates two clinical sites with over 100 beds total, processing over 100,000 samples and completing more than 1,000 bioequivalence studies to date.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioequivalence Studies (BE/BA/PK) Bioavailability, bioequivalence, and pharmacokinetics studies conducted in PRU's licensed clinical units with 102 beds across two sites, equipped with emergency rooms, an accredited diagnostic lab, a temperature/humidity-controlled pharmacy, and a 5,000+ healthy-participant database. Used by generic and innovative drug developers to demonstrate therapeutic equivalence for global regulatory submissions.
• Clinical Trials (Phase I-IV) Phase I-IV interventional and observational clinical trials covering study feasibility and design, investigators meetings, project management, site management, and clinical monitoring under ICH-GCP standards. Targeted at pharmaceutical and biotech sponsors running drug-development programs across multiple regions.
• Bioanalytical Services Bioanalysis of drug substances and metabolites using LC-MS/MS, LC-MS, and UPLC technologies managed by Watson LIMS, including method development, validation, and sample analysis. Capacity supports 80+ BE/BA/PK studies per year, with a library of 250+ validated analytical methods across a wide range of compounds.
• Training Services Professional training programs covering GCP guidelines, GLP principles, GDSP, quality management system establishment, bioanalytical method validation, and LC-MS/MS operation and maintenance. Targeted at clinical research and laboratory professionals seeking formal compliance and technical training.
• Cross Sectional Services Integrated support services bundling medical writing, IRB/EC services, central laboratory services, IMP storage and distribution, data management, pharmacokinetics evaluation, statistical analysis, and CTD/eCTD study reporting. Provides pharmaceutical and biotech sponsors with end-to-end clinical development support beyond core BE/BA/PK and trial execution.

Quantifiable outcome

• Study initiation within 3 weeks from protocol approval to JFDA/EC final approval
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Arab Pharmaceutical Industry Consulting (APIC)coreOthersPRU and APIC operate as the same entity - Pharmaceutical Research Unit (PRU) also known as Arab Pharmaceutical Industry Consulting (APIC). The company provides comprehensive clinical development services including bioequivalence studies, clinical trials, bioanalysis, data management, and regulatory consulting to pharmaceutical clients across Asia, Africa, EU, and USA.

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• ICON plc: Top-tier global CRO with comprehensive clinical development and bioanalytical capabilities, including early-phase through post-approval; broad incumbent competing in adjacent BE/BA and Phase I markets.
• IQVIA: Largest global CRO offering fully integrated Phase I–IV, bioanalytical, biostatistics, and real-world evidence services — a broad incumbent whose BE/BA franchises compete with PRU for global generic-drug sponsor work.
• Pharmaron: China-based integrated drug R&D and CRO services platform covering discovery, bioanalytical, and clinical services — broad incumbent adjacent in service mix with strong global sponsor relationships.
• Syneos Health: Major full-service global CRO with Phase I-IV and bioanalytical offerings — a broad incumbent whose integrated services model contrasts with PRU's specialized BE/BA focus.
• Charles River Laboratories: Large global CRO providing discovery, preclinical, bioanalytical, and clinical services including early-phase development — broad incumbent whose bioanalytical and Phase I suites overlap with PRU's services.

Direct peers

• Worldwide Clinical Trials: Mid-sized global CRO with strong early-phase, bioequivalence, and bioanalytical capabilities; competing with PRU for bioequivalence work from US and EU generic drug sponsors.
• Veeda Clinical Research: India-headquartered CRO with bioequivalence, bioanalytical, and Phase I clinical services for global generic and innovator pharma — directly comparable in service mix and emerging-markets angle.
• Lambda Therapeutic Research: India-based CRO operating 200+ beds with strong focus on bioequivalence and bioavailability studies for global generic sponsors, comparable in BE/BA scope, regulatory inspection profile, and pharma-sponsor B2B GTM.
• Celerion: Lincoln, Nebraska-based clinical pharmacology and bioanalytical CRO specializing in early-phase clinical pharmacology, bioequivalence/bioavailability, and first-in-human studies — directly comparable to PRU's BE/BA and bioanalytical core services with strong US regulatory standing.
• Accutest Research Laboratories (now Aragen): Indian bioanalytical and BE CRO with large global footprint — comparable BE/BA and bioanalytical services for global generic sponsors and overlapping regulatory accreditations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=wYrWYrdKetU
• LinkedInlinkedin.com/company/prujordan
• Facebookfacebook.com/PRUJordan

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pru